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Background: Implantation of implantable cardioverter-defibrillators (ICD) from the left pectoral region is the
standard therapeutical method. Increasing numbers of system revisions due to lead dysfunction and infections will
consecutively increase the numbers of right-sided implantations. The reliability of devices implanted on the right
pectoral side remains controversially discussed, and the question of testing these devices remains unanswered.
Methods: In a prospectively designed study all 870 patients (60.0±14 years, 689 male) who were treated with a
first ICD from July 2005 until May 2012 and tested intraoperatively according to the testing protocol were analyzed.
The indication for implantation was primary prophylactic in 71.5%. Underlying diseases included ischemic
cardiomyopathy (50%), dilative cardiomyopathy (37%), and others (13%). Mean ejection faction was 27±12%.
Implantation site was right in 4.5% and left in 95.5%.
Results: Five patients supplied with right-sided ICD (13%, p = 0.02 as compared to left-sided) failed initial
intraoperative testing with 21 J. 3 patients were male. The age of the patients failing intraoperative testing with
right-sided devices appeared higher than of patients with left-sided devices (p = 0.07). The ejection fraction was
28±8%. All patients reached a sufficient DFT ≤ 21 J after corrective procedures.
Conclusion: Implantation of ICDs on the right side results in significantly higher failure rate of successful
termination of intraoperatively induced ventricular fibrillation. The data of our study suggest the necessity of
intraoperative ICD testing in right-sided implanted ICDs.
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Implantation of implantable cardioverter-defibrillators
(ICD) in patients with high risk for life threatening ven-
tricular arrhythmias is the standard therapeutical method
[1]. The implantation of ICDs from the left pectoral
region is accepted standard procedure, which has consid-
erably improved over time by the development of new
ICD-leads, shock algorithms, high energy defibrillators,
and quick energy supply following the introduction of a
new generation of capacitors ≥31 Joule (introduced 2005).
Yet, pathological reasons (e.g. thrombosis, infection, aban-
doned leads) on the left side may force to implant the de-
vices on the right side. With increasing implantations of
ICDs the number of system revisions due to lead dysfunc-
tion and/or infections will rise and the number of right-* Correspondence: andreas.keyser@klinik.uni-regensburg.de
1Department of Cardiothoracic Surgery, University Medical Center,
Regensburg, Germany
Full list of author information is available at the end of the article
© 2013 Keyser et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsided implantations will increase consecutively. The reli-
ability of devices implanted on the right pectoral side re-
mains controversially discussed. The few studies reporting
on right-sided implantations have unanimously found sig-
nificant higher thresholds as compared to devices im-
planted left pectorally, but none of the studies have
reported of failing initial intraoperative tests [2-8]. The
present study evaluates intraoperative initial testing failure
in right-sided implantations of ICDs in consecutive con-
temporary patients with a uniform protocol and arouses
the issue of ICD testing in these patients.Methods
Since 1996, our institution implanted 1668 ICDs. With
introduction of newly developed high energy devices (≥31
Joule devices) with quick energy supply the study was in-
augurated 2005. To avoid bias of the study all patients re-
quiring ICD therapy were included. Informed consentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Keyser et al. Journal of Cardiothoracic Surgery 2013, 8:77 Page 2 of 6
http://www.cardiothoracicsurgery.org/content/8/1/77was obtained from each patient and approval of the insti-
tutional review board is given. Within the study period
from July 2005 until May 2012, 876 patients received their
first ICD (1-, 2-, and 3-chamber) devices.
Exclusion criteria
Left ventricular thrombi were regarded as exclusion cri-
terion to reduce the risk of embolization with respect to
the intraoperative testing procedure. Patients requiring
epicardial defibrillator patches also were excluded as they
were not treated with endocardial defibrillator leads.
The primary endpoint of the study was patients failing
the initial intraoperative testing of the system implanted.
Surgery
All patients underwent general anesthesia for the opera-
tive procedure which was performed by a cardiac surgeon.
Leads were placed via a cephalic vein and/or subclavian
vein. Only dual coil defibrillation leads were implanted.
Left ventricular leads were positioned either endocardially
or epicardially. All devices were implanted subpectorally.
The devices were implanted on the left side in 831
(95.5%) of the patients. Due to occluded left subclavian
vein or pacemaker on the right side 39 patients were
treated with right sided devices.
All implanted systems were high energy ICDs with max-
imum deliverable shock energy ≥31 Joule (J) (Biotronic,
Boston Scientific, Medtronic, and St. Jude Medical). Ven-
tricular leads were placed in a right apical position, the dis-
tal end of the proximal coil near the atrium/superior caval
vein junction. An adequate ventricular sensing of >6 mV
and a pacing threshold of <1 V was attempted in all cases.
Any antiarhythmic therapy was recorded.
Testing
Initial testing was performed using active can and dual
coil transvenuos lead. The superior caval vein coil and
right ventricular coil was the cathode for the biphasic
shock. According to the testing protocol ventricular fibril-
lation (VF) was induced by T-wave shock or - if T-wave
shock failed to induce VF - by 50Hz pacing. The test
shock was programmed at delivered energy of 21 J. The
delivered energy of 21 J corresponds to a 10 J safety mar-
gin of a 31 J device. To avoid bias in the study, the 21 J
margin was chosen, even if the delivered energy of an im-
planted device might have exceeded 31 J. In case of on-
going VF external defibrillation followed to terminate VF.
If successful termination of VF could not be achieved with
internal electrodes, the defibrillation lead was repositioned
and testing was repeated, again with 21 J. Programming
reversed polarity, single coil, and relocation of the device
caudo-medially or laterally followed as further options if
the system still failed to terminate VF, each step being
tested again with 21 J.Statistical analysis
Statistical analysis was performed with Stata 10.1 SE for
Windows (StataCorp, College Station, TX, USA). Con-
tinuous data were first tested for normality with the
Shapiro-Wilk test and graphically with Quantile-Quantile
plots. If normally distributed, these data are presented as
mean (± standard deviation) or, if non-normally distrib-
uted, as median with interquartile range. Dichotomous
data were expressed as numbers and percentages. Univar-
iate comparisons were tested with Fisher’s exact test or
the Chi-square test for categorical variables. The t test
was used for continuous normally-distributed variables or
Mann-Whitney’s test for non-normally distributed data.
The tests were performed two sided and a p-value of
<0.05 was considered statistically significant.
Results
Due to left cavity thrombi four patients had to be ex-
cluded from the study. Another two patients requiring
epicardial defibrillator patches also had to be excluded. In
the investigated group of 870 patients operated within the
last six years no major adverse events including death,
stroke, and cardio-pulmonary depression occurred during
implantation and testing. 39 patients had right pectoral
implantation of their device (4.5%).
Overall, 38 (4.3%) patients had a DFT >21 J with the ini-
tial shock configuration and underwent system correction.
The mean age of patients failing the initial test with left
sided devices proved to be significant lower when com-
pared to the age of the general study population (60±14
years versus 51±14 years - ranging from 22 to 71 years,
p<0.0001). Mean age of the patients with right-sided de-
vices and failing the initial intraoperative test was compar-
able to the study population, and higher when compared
to left-sided devices failing the initial intaoperative test
(left 49.6±14 years, right 61.5±7 years, p=0.07). There
were 25 male and 13 female patients. The ejection fraction
was comparable in both groups. The initial test was failed
by a total of 38 ICDs, 33 were implanted on the left (87%)
and 5 on the right side (13%). The failing rate of implanted
devices on the right side appeared to be significant higher
than devices being implanted on the left side (p=0.023).
Demographic data are summarized in Table 1.
Of the 39 devices implanted right pectorally the indica-
tion for ICD implantation was prophylactic in 28 cases
according to the MADIT criteria [9]. The underlying diag-
nosis of non-ischemic dilated cardiomyopathy was found
in 16 of the 39 patients, the remaining 23 patients suf-
fered from ischemic cardiomyopathy. Underlying diseases
of the patients and indication for device implantation are
summarized in Table 2.
We supplied 16 patients with a VVI system; three of
them presented with chronic atrial fibrillation. A DDD-
system was provided in 16 patients: 6 of them suffered
Table 1 Successful versus unsuccessful initial
intraoperative testing
Left sided
implantation
Right sided
implantation
Total
Successful [n; %] 798; 96% 34; 87% 832
Unsuccessful [n; %] 33; 4% 5; 13% 38
Total 831 39 870
p-value (FET) 0.023
FET - Fisher’s exact test.
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lation, two patients from AV block II type Mobitz and AV
block III, respectively. Seven patients were treated with
cardiac resynchronization therapy (CRT-D) due to add-
itional left bundle branch block (Table 3). Right ventricu-
lar sensing was adequate in all patients with 10.8±3 mV.
The pacing threshold was 0.6±0.2 V/0.5 ms. None of the
patients received amiodarone or any other antiarhythmic
therapy at the time of implantation.
All patients successfully reached a DFT ≤ 21 J (that is a
safety margin > 10 J) by changing the position of the ICD-
lead, replacing the device and/or optimizing the shock
configuration (Table 4).
Discussion
As the implantation of ICDs from the left pectoral region
is accepted standard procedure, right sided implantations
remain an exception [2-8]. A glimpse into the future un-
veils an increasing number of system revisions due to lead
dysfunction and infections [10]. Consecutively the num-
ber of ICDs implanted in the right pectoral region will
increase, and the question of intraoperative testing in right-
sided devices will gain a new and more important quality.
Significant higher thresholds of right pectorally im-
planted ICDs as compared to left-sided implantations
have been reported, and most of the literature was pub-
lished prior to the introduction of high energy devices
with a new generation of capacitors with quick energy
supply [2-8]. A failing of intraoperative testing has so far
explicitly only been discussed in a case report [11].
Only the determination of the DFT or a safety margin of
10 J tested intraoperatively indicates appropriate function
of the implanted system. Furthermore, the detection ofTable 2 Baseline characteristics
Variable Left sided implantation
Successful [n=798] Unsuccessful [n=33]
Age [years] 60 ± 14 50 ± 14
Gender
Males 637 22
Females 161 11
Ejection fraction [%] 27 ± 12 24 ± 12
Comparisons. Age: Unsuccessful left versus Unsuccessful right: p=0.07.ventricular arrhythmias (VAs, e.g. ventricular tachycardia
and/or fibrillation), lead function, and system integrity are
checked while testing, latter to detect the rare case of de-
vice failure [12]. The aim of a safety margin of 10 J – as in
our study – lowers the probability of retesting. In addition,
testing a 10 J safety margin tends to have enough evidence
and is generally accepted [13].
In our study, designed to include all consecutive patients
(all comers), we found a failing first shock rate of 13% in
patients having their device implanted right pectorally. An
inadequate safety margin of less than 10 J is found in 6.2%
up to 17% of patients receiving an ICD (left sided) [14,15].
In left pectorally implanted ICDs, lead repositioning, de-
vice relocation, additional leads, and changing device po-
larity are recommended to avoid insufficient therapy, e.g.
failing of necessary cardioversion and/or defibrillation, if
the intraoperative test fails [16-18].
In the study of Kirk [7] one fourth (25) of the patients
received right-sided implants of ICDs. The study popu-
lation is rather small. Only one patient failed adequate
intraoperative DFT-testing. Neither Gold [8] nor we ex-
perienced such a high amount of patients presenting
contraindications for left-sided implants. As the popu-
lations obviously differ concerning indication to right-
sided implantation they seem not to be comparable.
Gold [8] used a DFT-protocol not being completed in
three patients (7.3%) with right-sided implants because of
high thresholds. Yet Gold does not describe alterations of
the implants to achieve appropriate intraoperative testing
results. And he found a near doubling of the mortality
rate among patients with right-sided implants in his fol-
low up. The question arouses whether there might be a
link between testing failure and mortality in the study of
Gold. We tested a safety margin, having found an initial
failing of the intraoperative test in 5 patients. All these five
patients achieved an appropriate safety margin of ≤21 J by
altering the ICD system implanted (see Table 4).
An adequate ventricular sensing of >6 mV (10.8±0.3 mV)
and a pacing threshold of <1 V (0.6±0.2 V/0.5 ms) was
achieved in all patients, prior to testing. As all our pa-
tients achieved these values we must question whether
right ventricular stimulation threshold alone has enough
evidence for appropriate device function [19]. Five of ourRight sided implantation
p-value Successful [n=34] Unsuccessful [n=5] p-value
< 0.0001 63 ± 13 62 ± 7 0.77
0.08 27 3 0.57
7 2
0.15 26 ± 12 28 ± 8 0.72
Table 3 Indications for the implantable defibrillator (ICD) implantation
Left implantation Right implantation
DCMA ICMB OtherC DCM ICM Other
Successful [n; %] 289; 93% 404; 98% 105; 100% 13; 81% 21;91% 0
Failure [n; %] 23; 7% 10;2% 0; 0% 3; 19% 2;9% 0
p < 0.0001 (FET) p = 0.63 (FET)
PrimaryD SecondaryE Primary Secondary
Successful [n; %] 566; 96% 232; 97% 26; 77% 2;40%
Failure [n; %] 25; 4% 8; 3% 8; 23% 3; 60%
p = 0.69 p = 0.12
VVIF DDDG CRTH VVI DDD CRT
Successful [n; %] 496; 97% 204; 94% 98; 96% 14; 88% 13; 81% 7; 100%
Failure [n; %] 17; 3% 12; 6% 4; 4% 2; 12% 3; 19% 0, 0%
p = 0.34 (FET) p = 0.82 (FET)
FET – Fisher’s exact test.
ADCM – Nonischemic dilatative cardiomyopathie.
BICM – Ischemic cardiomyopathy.
COther – Hypertrophic obstructive cardiomyopathy, amyloidosis, fibrosis.
DPrimary – Primary prevention indication.
ESecondary – Seconardy prevention indication.
FVVI One chamber ICD.
GDDD Dual chamber ICD.
HCRT Cardiac resynchronization therapy.
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to failing shock at the first attempt. Thus, our data will
not strain the conclusion to refrain from intraoperative
testing as a consequence of an adequate right ventricular
threshold when implanting devices right pectorally.
Four of our 39 patients failing the initial intraoperative
test had pacemaker leads implanted prior to the ICD im-
plantation. The abandoned right ventricular lead of three
of our six patients with right-sided devices might have
had an impact on the testing procedure, even though
Glikson has shown no increased risk of abandoned right
ventricular leads in patients being supplied with left-
sided ICDs [20].
Amiodarone is reported to have an impact on failing
therapies in patients supplied with an ICD [14,21].
Napp therefore recommends intraoperative ICD testing
in these cases [21]. As Napp especially recommends
testing in young patients treated with amiodarone, and
as Napp questioned the need of intraoperative testingTable 4 Corrective measures in patients with primary right si
No Age [years] Gender Pace/sense Lead
reposit
1 50 Male 0.5 V; 0.5 ms/14 mV 1
2 70 Male 0.7 V; 0.5 ms/11 mV 1
3 64 Female 0.4 V; 0.5 ms/16 mV 1
4 63 Male 0.9 V; 0.5 ms/10 mV 1
5 61 Female 0.7 V; 0.5 ms/15 mV 1
ANo of intraoperative shocks; (no of external defibrillations).in his title we must stress, that in absence of medica-
tion with amiodarone abstaining from testing cannot be
recommended for right pectorally implanted ICDs. None
of our patients failing the initial intraoperative test with
right sided devices was treated with amiodarone or any
other antiarhythmic medication perioperatively.
The need of cardioversion and/or defibrillation might
be necessary as well when antitachycardia pacing (ATP)
as alternative therapy of VAs for these severe arrhythmias
fails [22]. Even if up to 80% of VAs may be treated suffi-
ciently with ATP, this different mode of therapy cannot
justify arguing against intraoperative testing, as Viskin
concludes [23].
The main arguments against intraoperative testing are
major adverse events such as intractable VF, hemodynamic
deterioration, neurological impairment, and death [24-26].
Death in accordance to defibrillator testing has a preva-
lence of 0.016% in the Canadian population of 19067 pa-
tients through 0.2% of 440 patients published by Alter,ded implantation
ion
Dual→ single
coil lead
Reverse
polarity
Device
reposition
Total no
of shocksA
1 5 (2)
3 (1)
1 1 7 (3)
3 (1)
1 3 (1)
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served in 0.026% in the Canadian study through 0.5% by
Alter [24,25]. The Canadian study is being multiply cited
in the use for arguments against intraoperative testing.
But Healey could verify these results in his study of 2173
patients finding no differences in the perioperative com-
plications in patients having been tested or not [28]. In
our total collective of 1668 patients treated since 1996
we observed no stroke and no deaths related to intraop-
erative testing. An adequate surgical implantation time
as well as a strict agreement in the operating theatre
concerning therapeutically procedures in case of intract-
able VF enhances the safety of a patient.
Stickberger et al. assumed an efficacy of about 5%
when additional modifications of the implanted systems
are necessary to achieve an adequate DFT [29]. Our sys-
tem revisions after failed initial testing, however, were
uniformly successful.
Finally, Strickberger states that the elimination of DFT
or safety margin testing offers the opportunity to treat
more patients with ICDs [29]. But would we willingly
accept a high failing rate in our patients, especially when
implanting devices right-sided? Even if ICDs represent a
life-saving tool in the therapy of sudden onsets of VAs
physicians should not abandon the standard of care for
their patients.
Conclusion
The development of new ICD-leads, shock algorithms,
high energy defibrillators, and quick energy supply has
improved the ICD devices. Nevertheless, the implantation
of ICDs on the right side results in significantly higher
failure rate of successful terminating intraoperatively in-
duced ventricular fibrillation. Alterations of the implanted
system such as lead repositioning, device relocation, and
changing device polarity are effective means to achieve
sufficient sensing of VAs and an appropriate safety margin
to terminate life threatening VAs. The data of our study
strongly suggest the necessity of intraoperative ICD test-
ing in right-sided implanted ICDs.
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